CompletedPhase 1/2

Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis

United States8 participantsStarted 2017-03-13

Plain-language summary

The primary aim of this study will be to examine the diagnostic utility of 18-F Florbetapir PET/MR (Positron Emission Tomography/Magnetic Resonance) in imaging patients with pathologically-confirmed systemic amyloidosis involving the peripheral nerves and compare these results to non-amyloid diseased controls.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults: 18-100 * Pathologically-confirmed peripheral nerve amyloidosis or pathologically-confirmed non-amyloid causes of peripheral neuropathy Exclusion Criteria: * Metallic devices that are not MR safe (cardiac pacers, stents, aneurysm coils, etc.) * Claustrophobia * BMI over 38

What they're measuring

Locations of peripheral nerve 18-F Florbetapir uptake

Timeframe: 50-120 minutes post injection

Pattern of F-18 Florbetapir uptake (Heterogeneous vs. Homogeneous, focal vs. diffuse)

Timeframe: 50-120 minutes post injection

Trial details

NCT IDNCT03019029

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-03-24

View on ClinicalTrials.gov More Amyloidosis trials